Posts by Mike Mooney
Understanding and Responding to FTD Behaviors
Behavioral symptoms associated with FTD often present significant challenges, not only for the individual diagnosed but also for their care partners. FTD behaviors, such as disinhibition, apathy, compulsivity, or loss…
Read MoreAFTD Grantee Leads Basic Science Study Exploring Role of Protein in Tau-Based Disorders like CBD
A recent study examines the role of chromogranin A (CgA) in disorders caused by dysfunctional tau protein. The study expands our foundational knowledge of these forms of FTD and opens…
Read MorePave the Path Forward This Giving Tuesday
AFTD Persons with FTD Advisory Council member Sandy Howe and her husband, Dirk, are sharing their story this Giving Tuesday to raise awareness about FTD and provide support for other…
Read MoreStudy Investigates if Clinical PSP Diagnoses Match Neuropathology in a National Dataset
A study published in the medical journal Alzheimer’s & Dementia finds disagreement between progressive supranuclear palsy (PSP) diagnoses made in-clinic and brain autopsies in the National Alzheimer’s Coordinating Center’s (NACC)…
Read MoreAmylyx Pharmaceuticals Ends PSP Trial of AMX0035
Amylyx Pharmaceuticals announced recently that it would end its phase 2b trial of its drug AMX0035 for the treatment of progressive supranuclear palsy (PSP). The trial will not proceed to…
Read MoreAFTD and ADDF Award $2.5 million to Vesper Biotechnology for Drug VES001 Clinical Trial in FTD
The Association for Frontotemporal Degeneration (AFTD) and the Alzheimer’s Drug Discovery Foundation (ADDF) recently awarded $2.5 million as part of their shared funding opportunity called the Treat FTD Fund to Danish biotechnology…
Read More
